{"id":"fpa144","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Decreased appetite"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"FPA144 selectively targets FGFR2b, a receptor involved in fibroblast growth factor signaling that promotes tumor cell proliferation and survival in certain cancers. By blocking this pathway, the drug aims to reduce tumor growth and inhibit the formation of new blood vessels that feed tumors. This mechanism is particularly relevant in gastric and gastroesophageal junction cancers that express high levels of FGFR2b.","oneSentence":"FPA144 is a monoclonal antibody that blocks fibroblast growth factor receptor 2b (FGFR2b) to inhibit tumor growth and angiogenesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:32:53.647Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer and gastroesophageal junction cancer with FGFR2b overexpression"}]},"trialDetails":[{"nctId":"NCT02318329","phase":"PHASE1","title":"Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Five Prime Therapeutics, Inc.","startDate":"2014-11","conditions":"Advanced Solid Tumors, Gastric Cancer, Transitional Cell Carcinoma of the Bladder","enrollment":79},{"nctId":"NCT03694522","phase":"PHASE2","title":"A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Five Prime Therapeutics, Inc.","startDate":"2018-09-14","conditions":"Gastric Cancer","enrollment":155},{"nctId":"NCT03343301","phase":"PHASE1","title":"A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer","status":"COMPLETED","sponsor":"Five Prime Therapeutics, Inc.","startDate":"2017-11-30","conditions":"Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic, Gastric Cancer","enrollment":12},{"nctId":"NCT05913115","phase":"PHASE1","title":"A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-06-12","conditions":"Gastric or Gastroesophageal Cancer","enrollment":6},{"nctId":"NCT03801278","phase":"","title":"An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer","status":"NO_LONGER_AVAILABLE","sponsor":"Five Prime Therapeutics, Inc.","startDate":"","conditions":"Recurrent Bladder Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bemarituzumab"],"phase":"phase_2","status":"active","brandName":"FPA144","genericName":"FPA144","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FPA144 is a monoclonal antibody that blocks fibroblast growth factor receptor 2b (FGFR2b) to inhibit tumor growth and angiogenesis. Used for Gastric cancer and gastroesophageal junction cancer with FGFR2b overexpression.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}